Genomic Health Study Shows Positive Data

Genomic Health Study Shows Positive Data

Genomic Health said a study of its Oncotype DX Genomic Prostate Score (GPS) test validate the test as an independent predictor of adverse pathology as a measure of tumor aggressiveness in men with localized prostate cancer. A second analysis reinforces that the test significantly increases use and persistence on active surveillance. The company said results from 258 patients demonstrated that use of the test changed initial treatment recommendations for 23% […]

Read More ˃